Burtenshaw said she believes Fluence is solving "one of the largest impediments" to access psychedelics-assisted therapy: training the next generation of qualified therapists to administer it. Neo Kuma invested $250,000 in the company's $3 million seed round earlier this year.

"We see the Fluence platform as a key component of the necessary infrastructure to widen access to existing treatments and to catalyze adoption of MDMA and psilocybin," she said.